Avoiding serotonin syndrome: The nature of the interaction between tramadol and selective serotonin reuptake inhibitors;Evitando el síndrome de serotonina: La naturaleza de la interacción de drogas entre tramadol e inhibidores selectivos de recaptación de serotonina

Annals of Pharmacotherapy

Volumn 46, Issue 12, 2012, Pages 1712-1716

  Nelson, Elana M ^a,b   Philbrick, Ann M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b TRUMAN MEDICAL CENTER   (United States)

Author keywords

Interaction; Selective serotonin reuptake inhibitor; Serotonin syndrome; SSRI; Tramadol

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; NORFLUOXETINE; PAROXETINE; SEROTONIN; SEROTONIN RECEPTOR; SERTRALINE; TRAMADOL; VENLAFAXINE;

ANALGESIC ACTIVITY; AREA UNDER THE CURVE; BODY TEMPERATURE; CASE STUDY; CHRONIC PAIN; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG METABOLISM; ENANTIOMER; FOOD INTAKE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MEDLINE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN INTERACTION; PSYCHOPHARMACOTHERAPY; RACEMIC MIXTURE; REVIEW; RISK FACTOR; SEROTONIN SYNDROME; SEROTONINERGIC NERVE CELL; STEREOCHEMISTRY; SYSTEMATIC REVIEW; WAKEFULNESS;

ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; PHARMACOGENETICS; SEROTONIN; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; TRAMADOL;

EID: 84872258518     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q748     Document Type: Review

References (22)

1. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:85-102.
2. Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 1991;27:7-17.
3. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112-20. doi: 10.1056/NEJMra041867
4. Wilffert B, Swen J, Mulder H, et al. From evidence based medicine to mechanism based medicine. reviewing the role of pharmacogenetics. Int J Clin Pharm 2011;33:3-9. doi: 10.1007/s11096-011-9485-2
5. Pedersen RS, Damkier P, Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006;62:513-21. doi: 10.1007/s00228-006-0135-x
6. Di Patti F, Fanelli D, Pedersen RS, Giuliani C, Torricelli F. Modelling the pharmacokinetics of tramadol: On the difference between CYP2D6 extensive and poor metabolizers. J Theor Biol 2008;254:568-74. doi: 10.1016/j.jtbi.2008.06.005.
7. Mandrioli R, Mercolini L, Saracino MA, Raggi MA. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2012;19:1846-63.
8. Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology (letter). J Clin Psychopharmacol 2002;22:440-1.
9. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med 1999;92:474-5.
10. John AP, Koloth R. Severe serotonin toxicity and manic switch induced by combined use of tramadol and paroxetine (letter). Aust N Z J Psychiatry 2007;41:192-3.
11. Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol-sertraline coadministration (letter). Clin Neuropharmacol 2004; 27:150-1.
12. Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram (letter). Am J Psychiatry 2004;161:1129.
13. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother 1997;31:175-7.
14. Nayyar N. Serotonin syndrome associated with sertraline, trazodone and tramadol abuse (letter). Indian J Psychiatry 2009;51:68. doi: 10.4103/0019-5545.44913
15. Egberts AC, Ter Borgh J, Brodie-Meijer CC. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Int Clin Psychopharmacol 1997;12:181-2.
16. Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram (letter). Age Ageing 2011;40:528. doi: 10.1093/ageing/afr017
17. Pilgrim JL, Gerostamoulos D, Drummer OH. Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. Int J Legal Med 2011;125:803-15. doi: 10.1007/s00414-010-0536-3
18. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005;95:434-41. doi: 10.1093/bja/aei210
19. Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc) 2008;44:827-36. doi: 10.1358/dot.2008.44.11.1289441
20. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective Odemethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312-23.
21. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007;82:41-7. doi: 10.1038/sj.clpt.6100152
22. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60: 636-44. doi: 10.1016/S0009-9236(96)90211-8